Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SABiosciences Corp.

Division of Qiagen NV
www.sabiosciences.com

Latest From SABiosciences Corp.

Qiagen Moves Into Next-Gen Sequencing

Qiagen has acquired privately held Intelligent Bio-Systems, a developer of next-generation sequencing (NGS) instruments aimed at the clinical research market. IBS’ technology, along with a newly expanded collaboration with bioinformatics provider SAP, is the cornerstone of a new NGS initiative at Qiagen.

Medical Device Strategy

In Vitro Diagnostics: The Quest For Growth

This article first appeared in Medtech Insight, October 2010.
Medical Device

Taking Stock Of Qiagen

Since its acquisition of Digene in 2007, Qiagen's business mix has shifted significantly towards molecular diagnostics even as the company remains true to its founding premise of making things simpler for customers. It has broadened its skill set in nucleic acid analysis with multiple acquired and licensed technologies for platform development while focusing on high volume tests in women's health and infectious diseases and new ties with pharma. Expect its acquisition pattern to continue.
Medical Device Business Strategies

In Vitro Diagnostics: The Quest for Growth

The global economic downturn has put pressure on large, consumer-based in vitro diagnostic markets, such as diabetes glucose-testing, driving down sales, pricing, and profits. As a result, the IVD industry is actively seeking out higher growth opportunities to offset this impact-and it is finding solutions in several areas, branching into underserved emerging markets like China and India and targeting higher-growth clinical segments such as cancer, women's health, and infectious disease. But perhaps the biggest opportunity for future growth lies in the field of molecular diagnostics, particularly products that address the move toward more personalized care. Suppliers well positioned to take advantage of this opportunity are likely to experience strong growth ahead.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • SuperArray
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Qiagen NV
  • Senior Management
  • Li Shen, Pres.
  • Contact Info
  • SABiosciences Corp.
    Phone: (301) 682-9200
    6951 Executive Way
    Frederick, MD 21703
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register